ViGenCell (308080.KQ) shares surged ahead of a formal oral presentation at the American Society of Clinical Oncology (ASCO) 2026.
According to the Korea Exchange, ViGenCell shares were trading at 9,600 won as of 2:57 p.m. Tuesday, up 29.91% from the previous day. The gain is seen as reflecting expectations over the disclosure of research results, after the company was selected for a formal oral presentation at the ASCO meeting that opens May 29 in Chicago.
At the conference, ViGenCell will unveil Phase 2 clinical trial results of its cell therapy "VT-EBV-N." The company plans to focus on the clinical outcomes of VT-EBV-N in suppressing recurrence and extending survival, which are considered key challenges in cancer treatment. The Phase 2 results confirmed significant effects in reducing recurrence risk and improving survival, suggesting the potential to improve patient prognosis. In cancer treatment, recurrence is a critical factor that substantially lowers patient survival rates, and effective strategies to suppress it remain an unmet need.
The selection is known to be the first case in which a Korean company has been chosen for a formal oral presentation session at ASCO based on cell therapy clinical data. The presentation will be delivered by Professor Jun Young-woo of Yeouido St. Mary's Hospital at the Catholic University of Korea, who led the clinical trial.
"Protecting patients' lives from the threat of recurrence is the ultimate goal of cancer treatment, and VT-EBV-N has proven that potential through actual clinical data," a company official said. "We will accelerate global partnerships to enhance corporate value and provide a new treatment option for patients."
